Biologic therapy and pregnancy outcomes in women with rheumatic diseases.
Vinet
Evelyne
E
Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada. evelyne.vinet@mail.mcgill.ca
Pineau
Christian
C
Gordon
Caroline
C
Clarke
Ann E
AE
Bernatsky
Sasha
S
D000069594:Abatacept; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use; D053590:Interleukin 1 Receptor Antagonist Protein / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011256:Pregnancy Outcome; D012216:Rheumatic Diseases / Q000188:drug therapy*; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018796:Immunoconjugates; D053590:Interleukin 1 Receptor Antagonist Protein; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000069594:Abatacept